Thermo Fisher Scientific has completed its acquisition of CorEvitas, a provider of real-world evidence for approved medical treatments and therapies, for $912.5 million. Real-world evidence is a high growth market segment as pharmaceutical and biotechnology customers, as well as regulating bodies, are increasingly looking to monitor and evaluate the safety of approved therapies and examine […]
